Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 184 of the 185 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Neurotrophins are important regulators of neuronal and non-neuronal functions. As such, the neurotrophins and their receptors, the tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases, has attracted intense research interest and their role in multiple diseases including Alzheimer’s disease has been described. Attempts to administer neurotrophins to patients have been reported, but the clinical trials have so far have been hampered by side effects or a lack of clear efficacy. Thus, much of the focus during recent years has been on identifying small molecules acting as agonists or positive allosteric modulators (PAMs) of Trk receptors. Two examples of successful discovery and development of PAMs are the TrkA-PAM E2511 and the pan-Trk PAM ACD856. E2511 has been reported to have disease-modifying effects in preclinical models, whereas ACD856 demonstrates both a symptomatic and a disease-modifying effect in preclinical models. Both molecules have reached the stage of clinical development and were reported to be safe and well tolerated in clinical phase 1 studies, albeit with different pharmacokinetic profiles. These two emerging small molecules are interesting examples of possible novel symptomatic and disease-modifying treatments that could complement the existing anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. This review aims to present the concept of positive allosteric modulators of the Trk receptors as a novel future treatment option for Alzheimer’s disease and other neurodegenerative and cognitive disorders, and the current preclinical and clinical data supporting this new concept. Preclinical data indicate dual mechanisms, not only as cognitive enhancers, but also a tentative neurorestorative function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) A schematic representation of Trk receptor expression summarized from [21,24,25,26,27] and the Human Protein Atlas initiative (https://www.proteinatlas.org, accessed on 16 June 2024) where red indicates high levels and blue indicates low levels of expression. Figures (b,c) are RNAseq data from Allen Brain Map, Allen Institute for Brain Science; Human multiple cortical areas—SMART-seq (https://celltypes.brain-map.org/rnaseq, accessed on 16 June 2024). (b) This data set includes single-nucleus transcriptomes from 49,495 nuclei across multiple human cortical areas. Individual layers of cortex were dissected from tissues covering the middle temporal gyrus. (c) The data set includes single-cell transcriptomes from 76,533 total cells derived from two post-mortem human brain specimens in the primary motor cortex.](https://figures.cochat.ai/paper-figures/749de766437f49e999410a99fe443e04/positive-allosteric-modulators-of-trk-receptors-for-the-treatment-of-alzheimers-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies identify TrkB positive allosteric modulators as stabilizers of induced plasticity, converting transient synaptic change into a more durable circuit state [114,115].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 3×
“These pathways are activated upon ligand binding and autophosphorylation of tyrosine (Y) 674/675 that governs the catalytic activity of the kinase activity.”
BackgroundPurification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 2×
“…tumor necrosis factor receptor superfamily [19]. from NGF, the mammalian family of neurotrophins includes brain-derived neurotrophic factor (BDNF) [9,10], NT-3 [11,12], and NT4/5 [13–15], which bind to the cognate tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases, including…”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“Secreted pro-neurotrophins are processed by extracellular matrix proteases to produce the mature forms in a regulated cascade-like manner, as exemplified for pro-NGF [80].”
BackgroundRegulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
The trk proto-oncogene encodes a receptor for nerve growth factor
Klein, R., Jing, S., Nanduri, V., O'Rourke, E., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90419-y · Cited by 1,401
Huang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198
Cited by
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Designed NGF mimetics with reduced nociceptive signatures in neuronsPreprint
Schlichthaerle, T., Yang, A., Detraux, D., Johnson, D. E., Peach, C. J., Edman, N. I., Sniezek, C. M., Williams, C. A., Arora, S., Katiyar, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.14.648806 · Cited by 7
Turner-Ivey, B., Jenkins, D. P., & Carroll, S. L. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.03.012 · Cited by 4
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.3 · Cited by 4
Molecular determinants of signal transduction in tropomyosin receptor kinases
Enkavi, G. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.70135 · Cited by 3
Sanjai, M., Jeyabalan, J. B., Pandi, A. V., Saravanan, S. L., Clement, J. P., & Justin, A. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07327-5 · Cited by 2
Fereidouni, A., Nematollahi, S., Mathew, K. T., Favennec, V., Liceran, L., Aldenhoff-Kelly, C., Valdivieso, M. A., Trent, S., & Moradikor, N. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154063 · Cited by 1
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.1 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration
Roggiolani, E., Rosini, M., Minarini, A., & Basagni, F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03783
Beyond total BDNF: The proBDNF/mBDNF balance in substance use disorders
Anema, S. L., Melo, M. M., Ferri, S. L., Gumusoglu, S. B., Blackwell, K. T., & Shen, S. Q. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107531
Sazonova, N. M., Filippova, M. Y., Melnikova, M. V., Ребеко, А. Г., Кузнецов, Д. Н., Povarnina, P. Y., & Гудашева, Т. А. (2026) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2026-2-45-58
Forti, S. F., & Forti, F. L. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4030021
The expansion of kinase drug discovery: new targets, platforms and indications
Sokolov, A. V., Fabbro, D., Knapp, S., & Schiöth, H. B. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01551-y
Metadata
- Authors
- Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M.
- Affiliations
- Karolinska Institutet (SE)
- AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden
- AlzeCure Pharma (Sweden) (SE)
- Corresponding author
- Forsell, Pontus
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-07-28
- Volume
- 17
- Issue
- 8
- Pages
- 997
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC11357672
- OpenAlex
- W4401209031
- Cited by
- 14
- References
- 184
- Citations by year
- 2026: 7 · 2025: 7
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- positive allosteric modulators, Trk receptors, Alzheimer's disease, neurotrophins, TrkA, disease-modifying therapy, symptomatic treatment, anti-amyloid monoclonal antibodies, cognitive enhancement, neurorestoration, neurodegenerative diseases, receptor tyrosine kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.